Shuttle Pharmaceuticals Holdings (SHPH) Income from Continuing Operations (2021 - 2026)
Shuttle Pharmaceuticals Holdings (SHPH) posted quarterly Income from Continuing Operations of 2516613.0 for Q1 2026, up 20.14% year-over-year from 2094751.32 in Q1 2025, and up 13.6% quarter-over-quarter from 2912710.0 in Q4 2025.
Shuttle Pharmaceuticals Holdings (SHPH) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Shuttle Pharmaceuticals Holdings' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 2516613.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 20.14% year-over-year to 2516613.0; the TTM figure through Mar 2026 stood at 12019102.0 (down 28.06% YoY), while the FY2025 annual figure was 19701474.0, down 54.97% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 2516613.0, up from 2912710.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 368462.0 in Q2 2022, with the low at 4223323.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 1995490.0 (2023), against an average of 2057660.94.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations sank 492.21% in 2022, then jumped 50.69% in 2024.
- Shuttle Pharmaceuticals Holdings' Income from Continuing Operations stood at 2718530.0 in 2022, then gained by 19.01% to 2201872.0 in 2023, then surged by 50.69% to 1085817.0 in 2024, then sank by 168.25% to 2912710.0 in 2025, then rose by 13.6% to 2516613.0 in 2026.
- Business Quant data shows SHPH's Income from Continuing Operations at 2516613.0 in Q1 2026, 2912710.0 in Q4 2025, and 2366456.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Shuttle Pharmaceuticals Holdings | 1.89 Mn | 1.89 Mn | - | -2.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.52 Mn |
| Dec 31, 2025 | -2.91 Mn |
| Sep 30, 2025 | -2.37 Mn |
| Jun 30, 2025 | -4.22 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | -1.09 Mn |
| Sep 30, 2024 | -3.25 Mn |
| Jun 30, 2024 | -1.90 Mn |
| Mar 31, 2024 | -1.86 Mn |
| Dec 31, 2023 | -2.20 Mn |
| Sep 30, 2023 | -1.78 Mn |
| Jun 30, 2023 | -2.00 Mn |
| Mar 31, 2023 | -975,097.00 |
| Dec 31, 2022 | -2.72 Mn |
| Sep 30, 2022 | -998,425.00 |
| Jun 30, 2022 | -368,462.00 |
| Mar 31, 2022 | -681,839.00 |
| Dec 31, 2021 | -459,048.00 |
| Sep 30, 2021 | -216,961.00 |